Si-Bone today touted that France is adding the iFuse implant system to its List of Refundable Products and services, clearing it for reimbursement by the French National Healthcare System.
The decision comes following the favorable opinion of the National Commissions for the Evaluation of Medical Devices and Health Technologies (CNEDIMTS), the Santa Clara, Calif-based company said.
The reimbursement is slated to go into effect September 6 and will be effective for five years, Si-Bone said.
France’s CNEDIMTS released an opinion last December stating that the iFuse procedure’s “observed outcomes, including improvements in quality of life and work status, are sufficient to include iFuse on the list of Products and Services,” according to a press release.
The device won recommendations for indications as a second-line treatment of sacroiliac joint dysfunction caused by sacroiliac joint disruption or degenerative sacroiliitis in patients who’ve failed to respond to conservative treatment.
Earlier this month, Si-Bone said that its iFuse implant system has received positive coverage policies from 23 commercial health plans.
